The UK and US have forged a landmark trade agreement that will keep zero duties on UK medicine exports being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost spending on drugs through the NHS. This move ensures that duties on these crucial goods will remain at zero for a period of three years.
This deal comes after earlier statements to hike import taxes on branded pharmaceutical imports, with figures floated reaching double the cost.
"This agreement between the United Kingdom reinforces the worldwide climate for new treatments and establishes much-needed fairness to U.S.–U.K. drug exports," a statement declared.
Commercial Impact
Pharmaceuticals represent one of the the United Kingdom's biggest export categories to the US, which is by far the biggest buyer for large UK drugmakers.
Statistics indicate that in the year leading up to last September, the UK sold drugs totaling £11.1bn to the US. This value represented a significant portion of all goods exports in that timeframe.
"This guarantee safeguards jobs, stimulates funding and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement involves several specific changes from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to raise total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. In the past, refunds topped twenty percent.
Broader Context
The deal follows a long-running dispute between the sector and the ministers over medicine costs and NHS adoption.
This friction were intensified by arguments that US consumers were paying a premium for the same drugs than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been halted or scrapped, while major investments have been directed toward American operations.
A senior figure acknowledged that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the past decade.
